Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Discovery Laboratories has demonstrated that the use of its Afectair, improved delivery of nitric oxide under simulated neonatal ventilatory conditions for treating pulmonary hypertension in newborn infants.
Subscribe to our email newsletter
Afectair is a series of proprietary ventilator circuit patient interface connectors, that eases the delivery of any inhaled therapies to critical care patients requiring ventilatory support.
The in-vitro study demonstrated that with the use of Afectair, nitric oxide utilisation requirements to achieve desired inhaled nitric oxide dose decreased by 50 to 70% compared to current standard of care.
The Afectair resulted in as much as a 70% reduction in the amount of nitric oxide required to deliver the desired dose of the therapeutic gas when compared with standard treatment.
Discovery Laboratories R&D senior vice-president Russell Clayton said the results of the study suggest that Afectair has the ability to effectively deliver a medical gas directly to a critical care patient, while reducing the amount of medical gas needed to achieve a target dose.
The company intends to launch Afectair in the US and the European Union in 2012.